Medtronic has announced new developments aimed at improving access and flexibility for people living with type 1 and insulin-requiring type 2 diabetes in the United States. The company revealed that Medicare beneficiaries can now access the MiniMed 780G system paired with the Instinct sensor, manufactured by Abbott. Additionally, the U.S. Food and Drug Administration (FDA) has cleared this system for use with ultra rapid-acting insulins Fiasp and Lyumjev, as well as for insulin-requiring type 2 diabetes when used with the Instinct sensor.
“These milestones reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition,” said Que Dallara, EVP & president, Medtronic Diabetes. “By broadening sensor and insulin options for the MiniMed 780G system, we’re empowering more people to benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management—making everyday life a bit easier.”
The Instinct sensor offers up to 15 days of wear and is designed to be slim and discreet. With this addition, Medicare users have expanded options alongside existing sensors such as Simplera Sync and Guardian 4.
Access to technologies like the MiniMed 780G system can help automate insulin delivery by responding to glucose changes every five minutes. This automation may reduce glucose variability and lessen daily decision-making for users.
The FDA’s clearance of ultra rapid-acting insulins Fiasp and Lyumjev for use with the MiniMed 780G system provides patients with additional therapy options. Ultra rapid-acting insulins are designed to work faster than traditional rapid-acting types, which may help address post-meal blood sugar spikes if meal doses are missed or delayed.
According to Anders Carlson, MD, Associate Executive Director at International Diabetes Center in Minneapolis: “Bringing together the Instinct sensor, made by Abbott, with the well-established algorithm of the MiniMed 780G system makes for an extremely effective combination. I think anyone who requires insulin therapy to manage their diabetes, whether it’s type 1 or type 2 diabetes, can benefit from automated insulin delivery. I’m thrilled that the MiniMed 780G system with the Instinct sensor is now cleared for this population, so that more people living with type 2 diabetes will get access to this life-changing technology improving their day-to-day experience in managing their diabetes.”
The company notes that customers who previously placed orders through Medicare will proceed via standard billing processes according to eligibility requirements. Medtronic Diabetes is working with distribution partners to ensure timely shipment of eligible devices.
The company describes its mission as making diabetes management more predictable through advanced technology solutions developed over four decades. Medtronic plc is headquartered in Galway, Ireland.
Forward-looking statements in this announcement are subject to risks described in Medtronic’s filings with the Securities and Exchange Commission.
